ABSTRACT The vesicular nucleotide transporter (VNUT) is responsible for the vesicular storage and release of ATP from various ATP-secreting cells, and it plays an essential role in

purinergic signaling. Although extracellular ATP and its degradation products are known to mediate various inflammatory responses via purinoceptors, whether vesicular ATP release affects

steatohepatitis and acute liver injury is far less understood. In the present study, we investigated the effects of clodronate, a potent and selective VNUT inhibitor, on acute and chronic

liver inflammation in mice. In a model of methionine/choline-deficient diet-induced non-alcoholic steatohepatitis (NASH), the administration of clodronate reduced hepatic inflammation,

vesicular ATP release mediated by VNUT and reduced the intracellular level and secretion of triglycerides in isolated hepatocytes. These results suggest that VNUT-dependent vesicular ATP

release plays a crucial role in the recruitment of immune cells, cytokine production, and the aggravation of steatosis in the liver. Pharmacological inhibition of VNUT may provide

therapeutic benefits in liver inflammatory disorders, including NASH and acute toxin-induced injury. SIMILAR CONTENT BEING VIEWED BY OTHERS LIVER LIPOPHAGY AMELIORATES NONALCOHOLIC

STEATOHEPATITIS THROUGH EXTRACELLULAR LIPID SECRETION Article Open access 13 July 2023 THERAPEUTIC EFFECTS OF ISOSTEVIOL SODIUM ON NON-ALCOHOLIC FATTY LIVER DISEASE BY REGULATING AUTOPHAGY

VIA SIRT1/AMPK PATHWAY Article Open access 27 July 2022 INHIBITION OF HEPATIC OXALATE OVERPRODUCTION AMELIORATES METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS Article Open access 27

September 2024 INTRODUCTION Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in all regions of the world and a growing public health problem1. NAFLD represents a spectrum of

liver disease ranging from simple steatosis to pathologically more severe forms, such as non-alcoholic steatohepatitis (NASH) and cirrhosis. NAFLD is slowly progressive, but in certain

cases, it progresses rapidly. It is reported that the progression of each fibrosis stage takes 14.3 years in patients with NAFLD and 7.1 years in those with NASH2. Liver fibrosis is

considered the most important predictor of mortality in NAFLD, as the risks of liver-related and all-cause mortality increase exponentially with each fibrosis stage3. Thus, therapeutic

approaches for the prevention of disease progression are urgently needed. However, limited treatment options are currently available for NAFLD and its pathogenesis has not yet been fully

elucidated. NASH is defined as the presence of steatosis and inflammation, and the latter is the main independent risk factor for fibrosis progression4. Among the endogenous triggers of

liver inflammation, extracellular ATP and its degradation products, such as ADP and adenosine, have been demonstrated to be important danger signals that mediate a wide spectrum of

pathological processes in the liver5. Liver cells express various purinergic receptor subtypes6. For instance, purinergic receptor P2RX7, a key player in inflammation, was shown in rodents

to be involved in alcohol- or diet-induced steatohepatitis, as well as acetaminophen hepatotoxicity7,8,9. Recently, it was reported that purinergic receptor P2RX7 is expressed by

infiltrating monocytes and resident Kupffer cells in the livers of NASH-affected individuals10. Extracellular nucleotides are released from liver cells through three pathways: simple leakage

via cellular breakage, permeation through ATP-permeable channels in the plasma membrane such as connexin hemichannels and pannexin channels, and exocytosis (vesicular ATP release)6. A

recent study by Vinken and colleagues showed that connexin hemichannels are involved in ATP release from hepatocytes, and the inhibition of these hemichannels alleviates choline-deficient,

high-fat diet-induced NASH in mice11. They further demonstrated that the genetic depletion of pannexin 1 protected mice from acetaminophen-induced acute liver failure and diet-induced

NASH12. These studies suggest that not only purinergic signal receptors but also nucleotide release pathways are deeply involved in the progression of acute and chronic liver diseases.

Vesicular nucleotide transporter (VNUT) is responsible for the vesicular storage and release of ATP and plays an essential role in purinergic signal transmission13,14. In _Vnut_ knockout

(_Vnut__−/−_) mice, ATP-secreting cells such as neurons, epithelial cells, and immune cells lack the capacity to release vesicular ATP. Furthermore, _VNUT__−_/_−_ mice exhibit attenuated

pain perception, reduced inflammation, and increased insulin sensitivity15,16. We previously found that clodronate, a first-generation bisphosphonate, is a specific inhibitor of VNUT,

preventing vesicular ATP release and resulting in the blockade of purinergic chemical transmission in vivo14,16,17,18,19. Remarkably, the mode of action of clodronate is totally different

from that of clodronate encapsulated in liposomes used for macrophage depletion. As revealed by in vitro assays, clodronate itself directly, selectively, and strongly inhibits VNUT with a

half-maximal inhibitory concentration (IC50) value of 15.6 nM16,19. Recently, we found that hepatocytes also express VNUT and secrete ATP through a VNUT-mediated mechanism upon glucose

stimulation, and this ATP secretion does not occur in the hepatocytes of _Vnut__−/−_ mice20. Furthermore, _Vnut__−/−_ mice are protected from diet-induced steatohepatitis and fibrosis, which

suggests that VNUT is involved in pathological conditions of the liver. These findings led us to explore whether clodronate could be used to treat acute and chronic liver diseases. In the

present study, therefore, we examined the effect of clodronate administration on diet-induced NASH in mice. We also investigated whether clodronate is effective for d-galactosamine (GalN)-

and lipopolysaccharide (LPS)-induced acute liver injury. RESULTS PHARMACOLOGIC INHIBITION OF VESICULAR ATP RELEASE AMELIORATES MCD DIET-INDUCED STEATOHEPATITIS Purinergic signaling is

involved in hepatic inflammation and fibrosis, two of the major pathological features of NASH5. To investigate the effect of vesicular ATP release on these pathologies, we used a mouse model

of NASH induced by a methionine- and choline-deficient (MCD) diet. Ten-week-old C57BL/6 male mice were fed an MCD diet with daily subcutaneous injections of the vehicle or clodronate (20 

mg/kg/day). MCD diet-induced body weight loss and organ-to-body weight ratios were not altered by clodronate treatment (see Supplementary Fig. S1 online). After 4 weeks, we observed that

clodronate dramatically protected the mice against MCD diet-induced liver inflammation and fibrosis as indicated by their improved histology. As shown in Fig. 1A, hematoxylin–eosin (HE)

staining demonstrated that intralobular inflammatory foci, which are characteristic of NASH, were frequently observed in the livers of the MCD group but not in the clodronate-treated livers.

The NAFLD activity score, particularly the lobular inflammation score component, showed that clodronate ameliorated inflammation and liver damage (Fig. 1B). The numbers of F4/80-positive

macrophages were also significantly reduced in this group (Fig. 1A,B). Further, Picrosirius Red staining revealed reduced fibrosis progression in the clodronate-treated group as evidenced by

the NASH fibrosis staging (Fig. 1A,B). Consistent with this, the MCD diet induced increases in plasma osteopontin, a pro-inflammatory cytokine promoting liver fibrosis, and this effect was

completely prevented by clodronate treatment (Fig. 1C). Plasma ALT levels were similar between the vehicle- and clodronate-treated groups, both for the normal diet-fed and MCD diet-fed

groups (Fig. 1D). Interestingly, treatment with clodronate ameliorated not only inflammation and fibrosis, but also hepatic steatosis (Fig. 1E). Lipid analysis revealed that the liver

triglyceride contents were significantly reduced in the clodronate-treated group (Fig. 1F). The ameliorated steatohepatitis was accompanied by reduced inflammatory gene expression as

analyzed by quantitative RT-PCR (qRT-PCR). Clodronate-treated mice demonstrated significant protection from the upregulation of _Nlrp3_, _Il1β_, and _Tnfα_ (but not _Il6_) induced by the MCD

diet (Fig. 2A). In concert with the reduced numbers of infiltrating macrophages, we observed decreased expression of _F4/80_ mRNA and a trend toward the reduced expression of _Mcp1_ (Fig. 

2B) in MCD diet-fed mice treated with clodronate compared with the vehicle-treated control. This inhibition of cytokine gene expression was not accompanied by a reduction in the protein

levels of Il1β, Tnfα, or Mcp1 in the liver or plasma (see Supplementary Fig. S1 online). This is consistent with a previous report stating that TNFα protein levels in the liver only increase

up to 2 weeks after initiating the MCD diet, while _Tnfa_ mRNA expression, as well as osteopontin protein levels, increase after 4 weeks of MCD diet treatment21. Hepatic mRNA levels of the

fibrosis markers, _Timp1_ and _Col1a1_, revealed the protective effect of clodronate against MCD diet-induced liver fibrosis (Fig. 2C). Taken together, these data suggest that vesicular ATP

release promotes inflammation and fibrosis, as well as the development of steatosis in MCD diet-induced NASH. ORAL ADMINISTRATION OF CLODRONATE PREVENTS HIGH-FAT, HIGH-CHOLESTEROL

DIET-INDUCED STEATOHEPATITIS The fact that clodronate ameliorated the accumulation of lipids, as well as inflammation and fibrosis, led us to evaluate the contribution of VNUT to lipid

metabolism in a more relevant physiological context. To this aim, we used a mouse NASH model induced by a high-fat, high-cholesterol (HFHC) diet22. Mice were fed normal chow (NC) or the HFHC

diet for 24 weeks with or without the administration of clodronate (30 mg/kg/day) in the drinking water. We observed that the long-term oral administration of clodronate significantly

protected against HFHC diet-induced steatohepatitis. Clodronate provided a high level of protection from NASH as indicated by liver histology and quantified by the NAFLD activity score (Fig.

 3A,B). There was also a trend toward the reduction of fibrosis as evaluated by Picrosirius Red staining and NASH fibrosis staging (Fig. 3A,B), as well as _Timp1_ mRNA expression (see

Supplementary Fig. S2 online), in the livers of clodronate-treated mice. F4/80 staining revealed a significant decrease in mean hepatic macrophage number in HFHC diet-fed mice treated with

clodronate compared with the control group (Fig. 3A). Unlike with the MCD diet, long-term HFHC diet administration did not significantly increase the gene expression of _Nrlp3_, _Il1β_, or

_Tnfα_ (see Supplementary Fig. S2 online). The protein levels of IL1β, TNFα, and MCP1 in the liver and plasma were similar between the vehicle- and clodronate-treated mice (see Supplementary

Fig. S2 online). Plasma ALT was significantly reduced (Fig. 3C) and plasma osteopontin showed a trend toward reduction in the clodronate-treated group compared with the HFHC diet-fed

control (Fig. 3D). The HFHC diet resulted in similar levels of body weight gain in both groups (Fig. 3E). However, the relative liver weight was significantly lower in the clodronate-treated

group, suggesting ameliorated steatosis (Fig. 3F). Liver lipid analysis revealed that treatment with clodronate attenuated the HFHC diet-induced accumulation of lipids (Fig. 4A), among

which the triglyceride content was significantly reduced (Fig. 4B). The HFHC diet significantly decreased the serum triglyceride level and increased the total serum cholesterol compared with

the NC diet (Fig. 4C,D), as reported previously22, and these changes were not affected by clodronate treatment. To investigate the underlying mechanism involved, lipid metabolism-related

gene expression was analyzed. In the livers of NC diet-fed mice, the oral administration of clodronate significantly suppressed the expression of de novo fatty acid (FA) synthesis-related

genes including _Scd1_, _Acc_, and _Srebp1c_ (Fig. 4E). The expression levels of _Mttp_, a gene involved in very low density lipoprotein (VLDL) production and secretion, as well as _Apoa5_,

which encodes a protein that facilitates the catabolism of triglyceride-rich lipoproteins in the plasma and the accumulation of intracellular triglycerides in the liver23,24, were also

significantly reduced by clodronate treatment in NC-fed mice. _Pparα_, which encodes a transcriptional activator of genes involved in β-oxidation, was also significantly reduced by

clodronate treatment in NC diet-fed mice, although this was not accompanied by changes in _Cpt1a_, which encodes an enzyme catalyzing the import of fatty acid into the mitochondria. The HFHC

diet strongly suppressed the FA synthesis-related genes _Scd1_, _Acc_, and _Srebp1c_ and this was not affected by clodronate treatment. Conversely, the gene expression of _Dgat2_, a

triglyceride synthesis-related gene, and that of _Apoa5_ was significantly increased by clodronate treatment compared with the vehicle-treated control HFHC diet-fed mice. _Ppara,_ but not

_Cpt1a_, was significantly upregulated by HFHC feeding in the clodronate-treated group but not in the vehicle-treated group, which might in part have contributed toward the attenuation of

steatosis by activating β-oxidation. CLODRONATE PROTECTS AGAINST D-GALACTOSAMINE/LIPOPOLYSACCHARIDE-INDUCED LIVER INJURY Clodronate is reported to have anti-inflammatory effects on immune

cells such as macrophages and neutrophils through the inhibition of VNUT-dependent vesicular ATP release16,25. To test whether clodronate could exert beneficial effects on acute toxic liver

injury, 10-week-old C57BL/6 male mice were subjected to intraperitoneal injections of d-galactosamine (GalN) and lipopolysaccharide (LPS). Mice were pretreated with the saline vehicle or 50 

mg/kg of clodronate 1 h before GalN/LPS administration. At 6 h after GalN/LPS injection, the livers showed signs of congestion and significant increases in weight, while these changes were

apparently prevented by pre-treatment with clodronate (Fig. 5A,B). Treatment with clodronate ameliorated GalN/LPS-induced histological changes in the liver based on HE staining, including

the levels of parenchymal hemorrhage and inflammatory cell infiltration (Fig. 5C). Ly6G immunostaining and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)

staining confirmed reduced numbers of infiltrating neutrophils and apoptotic cells, respectively, in the livers of mice treated with clodronate (Fig. 5C–E). The attenuation of liver injury

was further evidenced by the decreased serum levels of ALT in the clodronate-treated group (Fig. 5F). Inflammatory gene expression in the liver was analyzed by qRT-PCR. At 6 h after GalN/LPS

administration, the clodronate-treated mice exhibited approximately two-fold lower mRNA levels of _Il1β_, _Il6_, _Tnfα_, and _Mcp1_ compared with the saline-treated mice (Fig. 6A). In

concert with the mRNA findings, clodronate administration significantly reduced the protein levels of IL6 and TNFα in the plasma (Fig. 6B), and IL6, TNFα, and MCP1 in the liver (Fig. 6C),

whereas clodronate treatment had no effect on IL1β. Extracellular ATP is known to induce inflammasome activation via P2X7 receptors and, thereby, IL-1β maturation and secretion26. However,

our results suggested that in this model, clodronate affected inflammasome-independent pathways of inflammation. EFFECT OF CLODRONATE ON INFLAMMATORY GENE EXPRESSION, ATP SECRETION, AND

TRIGLYCERIDE METABOLISM IN CULTURED MOUSE PRIMARY HEPATOCYTES Given the implications of crosstalk between immune cells and hepatocytes in the pathology of liver inflammation, we examined

whether clodronate could suppress cytokine expression in hepatocytes as it does in macrophages in vitro16 . We exposed mouse primary hepatocytes to LPS and observed a strong increase in the

mRNA expression of _Tnfa_, _Mcp1_, and _Il6_ based on qRT-PCR. However, pre-treatment with clodronate could not prevent these increases in cytokine mRNA expression in the primary hepatocytes

(Fig. 7A). Because glucose is reported to induce lipogenic gene expression and triglyceride accumulation in primary hepatocytes as in an overfeeding situation in vivo27, we exposed mouse

primary hepatocytes to Krebs–Ringer buffer containing high glucose concentrations with or without 10 µM clodronate. We observed the early release of ATP from hepatocytes after glucose

stimulation, and this release was significantly inhibited by the administration of clodronate (Fig. 7B). Consistent with the in vivo findings, clodronate also inhibited the glucose-induced

secretion and accumulation of triglycerides in primary hepatocytes (Fig. 7C,D). In this in vitro model, however, the mRNA expression of _Scd1_, _Srebp1c_, and _Cpt1a_ was not affected by

stimulation with glucose or treatment with clodronate (Fig. 7E). DISCUSSION It has been proposed that extracellular nucleotides serve as “metabolokines” that link inflammation and metabolic

processes in the liver5. Therefore, the functions of purinoceptors in various cellular components of the liver have been widely investigated. However, the importance of extracellular ATP

release pathways in liver pathology was less understood. In this study, we provided compelling evidence that vesicular ATP release via VNUT plays a pivotal role in acute and chronic

inflammation, as well as lipid metabolism in the liver, and we show that VNUT represents a potential therapeutic target for liver diseases. In our GalN/LPS-induced liver injury model,

clodronate reduced hepatic neutrophil infiltration, the apoptosis of hepatocytes, and inflammatory cytokine production. This experimental animal model recapitulates the clinical scenario of

fulminant hepatic failure in humans28. Low doses of LPS in combination with the specific hepatotoxic agent, D-GalN, which sensitizes hepatocytes to the lethal effects of LPS, induce the

production of inflammatory cytokines such as TNFα, IL-β, and IL-6, particularly in the macrophages, thereby promoting the infiltration of immune cells into the liver. Purinergic signaling is

known to regulate the chemotaxis, proliferation, differentiation, and release of inflammatory mediators of immune cells29. We previously reported that clodronate completely inhibits

vesicular ATP release from THP1, a human monocytic cell line, and that the deletion of extracellular ATP blocks TNFα release from THP1 cells induced by LPS administration16. Recently,

neutrophils were also reported to express VNUT in their secretory granules, which mediates vesicular ATP release to promote neutrophil migration25. In the present study, we demonstrated that

clodronate also suppresses the secretion of ATP from hepatocytes. Our results suggest that VNUT plays an important role in the recruitment of immune cells to the liver and in the production

of cytokines by these cells under acute inflammation. The mechanisms underlying NASH development are multifactorial and comprise insulin resistance, nutritional factors, adipose tissue

dysfunction, and the activation of inflammatory pathways30. We previously found that glucose-induced ATP secretion does not occur in the hepatocytes of _Vnut__−/−_ mice20, and ATP secretion

was inhibited by clodronate in the present study. These findings suggest that VNUT links nutritional status to the initiation of inflammation. In addition, extracellular ATP causes insulin

resistance in the liver31. Indeed, we previously found that _Vnut_−/− mice exhibit increased insulin sensitivity of the liver15. In the current study, we observed that the administration of

clodronate reduced steatosis and macrophage infiltration in both MCD diet-induced and HFHC diet-induced NASH models. In NASH, insulin resistance predisposes the liver to fat accumulation and

causes lipotoxicity, which induces hepatocellular apoptosis and the recruitment of immune cells, while the activation of pro-inflammatory pathways maintains insulin resistance in turn32. By

inhibiting vesicular ATP release both from the hepatocytes and immune cells, clodronate is expected to interrupt this vicious cycle in the microenvironment of the liver. Notably, clodronate

prevented the development of fibrosis in diet-induced NASH models. Purinergic signaling is implicated in the pathogenesis of hepatic fibrosis33. Adenosine acts on A2A receptors to increase

collagen production by hepatic stellate cells34. The treatment of human hepatic stellate cells with a P2X7 receptor antagonist is reported to suppress the activation of stellate cells

induced by LPS or the conditioned medium from LPS-stimulated mouse macrophages35. Therefore, it is suggested that clodronate prevents the progression of liver fibrosis by directly preventing

stellate cell activation and/or by affecting their cross-talk with macrophages. The blockade of vesicular ATP release by clodronate could be a potential therapeutic option for the treatment

of liver fibrosis. Concerning hepatic lipid metabolism, the genetic depletion of the P2X7 receptor was reported to reduce hepatic fat accumulation and lipogenesis-related gene expression

induced by a high-fat (HF) diet8. In our study, the oral administration of clodronate significantly suppressed the expression of de novo FA synthesis-related genes including _Scd1_, _Acc_,

and _Srebp1c_ in the liver of NC diet-fed mice. Given that the liver-specific knockout of _Acc_ or _Scd1_ was shown to protect mice from steatosis36,37,38, the attenuation of steatosis by

clodronate may be the consequence of the suppression of these genes. However, after 24 weeks of HFHC diet feeding, these de novo FA synthesis-related genes were strongly downregulated

regardless of clodronate treatment. While the genes involved in triglyceride synthesis (_Dgat2_) and VLDL secretion (_Apoa5_) were relatively upregulated by clodronate in HFHC diet-fed mice,

the hepatic lipid content was reduced and the serum triglyceride and total cholesterol levels were unchanged in mice treated with clodronate compared with the control group. This suggests

that changes in the expression of these genes could form part of a compensatory mechanism. In addition to being directly affected by purinergic signaling as shown with our primary cultured

hepatocytes20, the development of steatosis could also have been influenced by inflammatory mediators in adipose tissue that induce systemic insulin resistance. Although the protein levels

of IL1β, TNFα, and MCP1 in the plasma were not altered in our experimental NASH models following the administration of clodronate, an effect of the changes in the local inflammatory

condition of the adipose tissue could not be excluded. The increased systemic and hepatic insulin sensitivity in VNUT-knockout mice also support this hypothesis15. Clodronate can be

intracellularly metabolized to an analog of ATP (AppCCl2p), which inhibits the mitochondrial ADP/ATP translocase39 and various other kinases such as PDGFRa, JAK2, JAK3, and FGFR240. These

pharmacological properties of clodronate may also explain the suppression of steatosis. However, we recently demonstrated that VNUT-knockout mice are also protected from NASH20. In this

earlier study, the inhibitory effect of clodronate on the triglyceride secretion from hepatocytes was canceled by 2-methylthio-ADP, indicating that clodronate suppresses triglyceride

secretion by blocking purinergic signaling. While clodronate liposomes induce the apoptosis of macrophages by inhibiting mitochondrial ADP/ATP translocase, clodronate alone does not affect

the viability of the human monocyte cell line, THP116. Furthermore, clodronate did not increase but instead reduced cell apoptosis in our LPS/D-Gal-induced acute liver injury model. Taken

together, the protective effect of clodronate against acute and chronic liver injury is expected to mainly depend on the VNUT–purinoceptor pathway. To better characterize the role of VNUT

and the mechanism of action of clodronate in NASH, further investigations using the conditional knockout approach and detailed biochemical analysis will be required. In our in vitro

experiment with primary hepatocytes, clodronate inhibited both the secretion and accumulation of triglycerides without affecting the mRNA expression of _Scd1_ and _Srebp1c_. These results

indicated that triglyceride accumulation was inhibited by clodronate via mechanisms other than the transcriptional regulation of de novo FA synthesis genes. A recent study demonstrated that

treating mice with _Apob_ antisense oligonucleotides decreases the secretion of VLDL without causing hepatic steatosis41. Without apolipoprotein B (apoB), which is essential for the hepatic

assembly and secretion of triglyceride-rich VLDL, triglycerides become trapped in the lumen of the endoplasmic reticulum (ER). This triggers ER autophagy followed by the oxidation of the

released FA, which, in turn, prevents steatosis. ADP was reported to stimulate apoB secretion through P2Y13 receptors31. We recently demonstrated that VNUT is partially colocalized with APOB

in hepatocytes and that glucose-induced triglyceride secretion from hepatocytes is blocked by a P2Y13 inhibitor20. Taken together, it is possible that clodronate reduces both the secretion

and accumulation of triglycerides by inhibiting P2Y13 signaling and apoB activity. Further studies will be required to clarify the role of purinergic signaling in the regulation of autophagy

and lipid metabolism. In summary, our study revealed that clodronate attenuated hepatic inflammation, fibrosis, and steatosis. The pharmacological inhibition of VNUT may represent a

potential therapeutic approach for the treatment of hepatic inflammatory and metabolic diseases. METHODS ANIMAL EXPERIMENTS C57BL/6 wild-type mice were obtained from Charles River

Laboratories Japan, Inc. Control mice were fed ad libitum with a normal chow (NC) diet (5.4% fat, CRF-1; Orient Yeast Co.) and kept under a 12-h light–dark cycle. The MCD group of mice was

fed a methionine- and choline-deficient diet (A02082002B; Research Diets) and the HFHC group was fed a high-fat, high-cholesterol diet (D09100301; Research Diets) that was enriched in fat

(40% kcal including premix shortening), fructose (22% by weight), and cholesterol (2% by weight). Animals were allowed ad libitum access to these diets for the indicated periods. Mice fed

the MCD diet received a daily subcutaneous dose of 20 mg/kg clodronate or the vehicle. Mice fed an HFHC diet were given 30 mg/kg clodronate daily or the vehicle alone in their drinking

water. For the analysis of acute liver injury, 10-week-old male mice received intraperitoneal (i.p.) injections of 700 mg/kg d-galactosamine (GalN) and 100 µg/kg lipopolysaccharide (LPS; _E.

coli_ 0111:B4). Mice were pretreated with saline or 50 mg/kg i.p. clodronate 1 h before GalN and LPS administration. All experiments were carried out in accordance with the approved

institutional guidelines and were approved by the Ethics Committees of Kyushu University, Graduate School of Medicine (approval number: A29-138-0) and the Kurume University School of

Medicine (approval number: 2020-115). HISTOLOGY Liver samples were fixed (4% paraformaldehyde), paraffin-embedded, sectioned, and stained with hematoxylin–eosin or Picrosirius Red.

Immunostaining was performed on paraffin-embedded sections using the F4/80 monoclonal antibody (1:200, Cat# MCA497GA; AbD Serotec) or Ly6G monoclonal antibody (1:200, Cat# 551459; BD

Biosciences). TUNEL staining was performed with the ApopTag Peroxidase In Situ Apoptosis Detection Kit (Cat# S7100; Millipore). The histological score was determined by a blinded

investigator using the Nonalcoholic Steatohepatitis Clinical Research Network histological scoring system for NAFLD42. The total NAFLD activity score (NAS) was calculated from the sum of the

individual scores for steatosis, lobular inflammation, and hepatocellular ballooning. Each parameter ranged from 0 to 2 (ballooning) or 3 (the other two scores), with 0 being normal and 2

or 3 being severe. Fibrosis staging was based on the NASH fibrosis stage and ranged from 0 to 442. The numbers of F4/80- or Ly6G-positive cells were counted in four high-power fields per

section using the BZ-X Hybrid Cell Count software (Keyence). The numbers of TUNEL-positive cells were counted in 16 high-power fields per section. BIOCHEMICAL ASSAYS The levels of alanine

aminotransferase (ALT) in the plasma were measured using a DRI-CHEM 3500 Chemistry Analyzer with the DRI-CHEM slide GPT/ALT-P III (Fujifilm). Serum osteopontin was analyzed with a mouse

osteopontin assay kit (Immuno-Biological Laboratories). The total liver lipid content was determined with Folch’s method43. Triglyceride, total cholesterol, and nonesterified fatty acid

(NEFA) levels were measured with the TG E-test, Cholesterol E-test, and NEFA C-test (Wako), respectively. The levels of IL1β, TNFα, IL6, and MCP1 in the plasma and liver lysate were analyzed

using the BD Cytometric Bead Array (BD Biosciences) according to the manufacturer’s instructions. A NovoCyte flow cytometer (ACEA Biosciences) was used to quantify the cytokine profiles.

ATP was determined with the Kinsiro ATP Luminescence Kit (Toyo B-Net). MRNA ANALYSES Total RNA was isolated from the mouse liver and primary hepatocytes using TRIzol Reagent (Invitrogen).

Reverse transcription with 1 µg of RNA was conducted using the QuantiTect Reverse Transcription Kit (Qiagen). Quantitative real-time PCR was used to determine the relative expression levels

of mRNA. The assays were performed with SYBR Premix Ex Taq II (Takara Bio) on the Applied Biosystems 7500 Real-Time PCR system. The primer sequences of the selected genes are provided in

Supplementary Table S1 online. Results were normalized to the expression of glyceraldehyde 3-phosphate dehydrogenase (Gapdh) and are shown as the fold change relative to gene expression in

the control mice or hepatocytes. PRIMARY CULTURE OF MOUSE HEPATOCYTES Primary hepatocytes were isolated from 10-week-old C57BL/6 male mice as previously described44. Hepatocytes were seeded

in 6-well, collagen-coated culture dishes at 2 × 106 cells per well in Dulbecco’s modified Eagle’s medium (Sigma-Aldrich) supplemented with 1 μM insulin, 2 mM l-glutamine, 10 IU/mL

penicillin, 10 IU/mL streptomycin, and 10% fetal bovine serum. For the analysis of cytokine gene expression in hepatocytes, primary mouse hepatocytes were washed three times and

pre-incubated for 30 min with Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, followed by stimulation with 1 µg/mL LPS or control medium. The pre-incubation and

stimulation steps were performed in the presence or absence of 10 µM clodronate. At 4 h after stimulation, the hepatocytes were collected for mRNA analysis. For the analysis of ATP and

triglyceride levels, primary hepatocytes were washed three times and pre-incubated for 20 min with glucose-free Krebs–Ringer bicarbonate buffer (10 mM HEPES-Tris, pH 7.4, 128 mM NaCl, 1.9 mM

KCl, 1.2 mM KH2PO4, 1.3 mM MgSO4, 26 mM NaHCO3, 2.4 mM CaCl2, 0.2% (w/v) bovine serum albumin, and 300 μM oleic acid) with or without 10 µM clodronate. After pre-incubation, the hepatocytes

were stimulated with Krebs–Ringer buffer containing 25 mM glucose with or without 10 µM clodronate for the indicated time. The culture supernatants and cell lysates were then subjected to

biochemical analysis. For the analysis of lipid gene expression, the hepatocytes were collected at 60 min after stimulation. All experiments were performed in duplicate at least three times.

STATISTICAL ANALYSIS All results are reported as the means ± standard error of the mean (S.E.M.). Statistical analyses were performed using GraphPad Prism 7.0 software (GraphPad Software).

The unpaired two-tailed Student’s _t_ test was used to assess significance when comparing two groups. Statistical significance between three or more groups was determined using two-way

analysis of variance (ANOVA) with Tukey’s or Dunnett’s post hoc test. Differences were considered statistically significant when the _P_ value was < 0.05. DATA AVAILABILITY The datasets

generated during the current study are available from the corresponding author on reasonable request. REFERENCES * Younossi, Z. M. _et al._ Global epidemiology of nonalcoholic fatty liver

disease—Meta-analytic assessment of prevalence, incidence, and outcomes. _Hepatology_ 64, 73–84 (2016). Article  PubMed  Google Scholar  * Singh, S. _et al._ Fibrosis progression in

nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies. _Clin. Gastroenterol. Hepatol._ 13, 643-654.e9 (2015). Article 

PubMed  Google Scholar  * Dulai, P. S. _et al._ Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. _Hepatology_ 65,

1557–1565 (2017). Article  CAS  PubMed  Google Scholar  * Argo, C. K., Northup, P. G., Al-Osaimi, A. M. S. & Caldwell, S. H. Systematic review of risk factors for fibrosis progression in

non-alcoholic steatohepatitis. _J. Hepatol._ 51, 371–379 (2009). Article  CAS  PubMed  Google Scholar  * Vaughn, B. P., Robson, S. C. & Burnstock, G. Pathological roles of purinergic

signaling in the liver. _J. Hepatol._ 57, 916–920 (2012). Article  CAS  PubMed  PubMed Central  Google Scholar  * Burnstock, G., Vaughn, B. & Robson, S. C. Purinergic signalling in the

liver in health and disease. _Purinergic Signal._ 10, 51–70 (2014). Article  CAS  PubMed  Google Scholar  * Iracheta-Vellve, A. _et al._ Inhibition of sterile danger signals, uric acid and

ATP, prevents inflammasome activation and protects from alcoholic steatohepatitis in mice. _J. Hepatol._ 63, 1147–1155 (2015). Article  CAS  PubMed  PubMed Central  Google Scholar  *

Blasetti Fantauzzi, C. _et al._ Deficiency of the purinergic receptor 2X7 attenuates nonalcoholic steatohepatitis induced by high-fat diet: Possible role of the NLRP3 inflammasome. _Oxid.

Med. Cell. Longev._ 2017, 8962458 (2017). Article  PubMed  PubMed Central  CAS  Google Scholar  * Hoque, R. _et al._ P2X7 receptor-mediated purinergic signaling promotes liver injury in

acetaminophen hepatotoxicity in mice. _Am. J. Physiol. Gastrointest. Liver Physiol._ 302, 1171–1179 (2012). Article  CAS  Google Scholar  * Baeza-Raja, B. _et al._ Pharmacological inhibition

of P2RX7 ameliorates liver injury by reducing inflammation and fibrosis. _PLoS ONE_ 15, e0234038 (2020). Article  CAS  PubMed  PubMed Central  Google Scholar  * Willebrords, J. _et al._

Inhibition of connexin hemichannels alleviates non-alcoholic steatohepatitis in mice. _Sci. Rep._ 7, 8268 (2017). Article  ADS  PubMed  PubMed Central  CAS  Google Scholar  * Willebrords, J.

_et al._ Protective effect of genetic deletion of pannexin1 in experimental mouse models of acute and chronic liver disease. _Biochim. Biophys. Acta Mol. Basis Dis._ 1864, 819–830 (2018).

Article  CAS  PubMed  Google Scholar  * Moriyama, Y., Hiasa, M., Sakamoto, S., Omote, H. & Nomura, M. Vesicular nucleotide transporter (VNUT): appearance of an actress on the stage of

purinergic signaling. _Purinergic Signal._ 13, 387–404 (2017). Article  CAS  PubMed  PubMed Central  Google Scholar  * Hasuzawa, N., Moriyama, S., Moriyama, Y. & Nomura, M.

Physiopathological roles of vesicular nucleotide transporter (VNUT), an essential component for vesicular ATP release. _Biochim. Biophys. Acta Biomembr._

https://doi.org/10.1016/j.bbamem.2020.183408 (2020). Article  PubMed  Google Scholar  * Sakamoto, S. _et al._ Impairment of vesicular ATP release affects glucose metabolism and increases

insulin sensitivity. _Sci. Rep._ 4, 6689 (2015). Article  CAS  Google Scholar  * Kato, Y. _et al._ Identification of a vesicular ATP release inhibitor for the treatment of neuropathic and

inflammatory pain. _Proc. Natl. Acad. Sci._ 114, E6297–E6305 (2017). Article  CAS  PubMed  PubMed Central  Google Scholar  * Mihara, H., Uchida, K., Koizumi, S. & Moriyama, Y.

Involvement of VNUT-exocytosis in transient receptor potential vanilloid 4-dependent ATP release from gastrointestinal epithelium. _PLoS ONE_ 13, e0206276 (2018). Article  PubMed  PubMed

Central  CAS  Google Scholar  * Maruyama, K. _et al._ The ATP transporter VNUT mediates induction of dectin-1-Triggered Candida nociception. _iScience_ 6, 306–318 (2018). Article  ADS  CAS 

PubMed  PubMed Central  Google Scholar  * Moriyama, Y. & Nomura, M. Clodronate: A vesicular ATP release blocker. _Trends Pharmacol. Sci._ 39, 13–23 (2018). Article  CAS  PubMed  Google

Scholar  * Tatsushima, K. _et al._ Vesicular ATP release from hepatocytes plays a role in the progression of nonalcoholic steatohepatitis. _Biochim. Biophys. Acta - Mol. Basis Dis. _1867,

166013 (2021). Article  CAS  PubMed  Google Scholar  * Sahai, A., Malladi, P., Melin-Aldana, H., Green, R. M. & Whitington, P. F. Upregulation of osteopontin expression is involved in

the development of nonalcoholic steatohepatitis in a dietary murine model. _Am. J. Physiol. Gastrointest. Liver Physiol._ 287, 264–273 (2004). Article  Google Scholar  * Clapper, J. R. _et

al._ Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. _Am. J. Physiol. Gastrointest. Liver

Physiol._ 305, 483–495 (2013). Article  CAS  Google Scholar  * Garelnabi, M., Lor, K., Jin, J., Chai, F. & Santanam, N. The paradox of ApoA5 modulation of triglycerides: Evidence from

clinical and basic research. _Clin. Biochem._ 46, 12–19 (2013). Article  CAS  PubMed  Google Scholar  * Shu, X., Nelbach, L., Ryan, R. O. & Forte, T. M. Apolipoprotein A-V associates

with intrahepatic lipid droplets and influences triglyceride accumulation. _Biochim. Biophys. Acta Mol. Cell Biol. Lipids_ 1801, 605–608 (2010). Article  CAS  Google Scholar  * Harada, Y.

_et al._ Vesicular nucleotide transporter mediates ATP release and migration in neutrophils. _J. Biol. Chem._ 293, 3770–3779 (2018). Article  CAS  PubMed  PubMed Central  Google Scholar  *

Schroder, K. & Tschopp, J. The Inflammasomes. _Cell_ 140, 821–832 (2010). Article  CAS  PubMed  Google Scholar  * Han, C. _et al._ The role of insulin and glucose in goose primary

hepatocyte triglyceride accumulation. _J. Exp. Biol._ 212, 1553–1558 (2009). Article  CAS  PubMed  Google Scholar  * Sebti, Y. _et al._ The LPS/d-galactosamine-induced fulminant hepatitis

model to assess the role of ligand-activated nuclear receptors on the NLRP3 inflammasome pathway in vivo. _Methods Mol. Biol._ 1951, 189–207 (2019). Article  CAS  PubMed  Google Scholar  *

Jacob, F., Novo, C. P., Bachert, C. & Van Crombruggen, K. Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory

responses. _Purinergic Signal._ 9, 285–306 (2013). Article  CAS  PubMed  PubMed Central  Google Scholar  * Buzzetti, E., Pinzani, M. & Tsochatzis, E. A. The multiple-hit pathogenesis of

non-alcoholic fatty liver disease (NAFLD). _Metabolism_ 65, 1038–1048 (2016). Article  CAS  PubMed  Google Scholar  * Chatterjee, C. & Sparks, D. L. Extracellular nucleotides inhibit

insulin receptor signaling, stimulate autophagy and control lipoprotein secretion. _PLoS ONE_ 7, e36916 (2012). Article  ADS  CAS  PubMed  PubMed Central  Google Scholar  * Peverill, W.,

Powell, L. W. & Skoien, R. Evolving concepts in the pathogenesis of NASH: Beyond steatosis and inflammation. _Int. J. Mol. Sci._ 15, 8591–8638 (2014). Article  CAS  PubMed  PubMed

Central  Google Scholar  * Ferrari, D. _et al._ Purinergic signaling in scarring. _FASEB J._ 30, 3–12 (2016). Article  CAS  PubMed  Google Scholar  * Che, J., Chan, E. S. L. & Cronstein,

B. N. Adenosine A2A receptor occupancy stimulates collagen expression by hepatic stellate cells via pathways involving protein kinase A, Src, and extracellular signal-regulated kinases 1/2

signaling cascade or p38 mitogen-activated protein kinase signaling path. _Mol. Pharmacol._ 72, 1626–1636 (2007). Article  CAS  PubMed  Google Scholar  * Jiang, S. _et al._ Potentiation of

hepatic stellate cell activation by extracellular ATP is dependent on P2X7R-mediated NLRP3 inflammasome activation. _Pharmacol. Res._ 117, 82–93 (2017). Article  CAS  PubMed  Google Scholar

  * Ducheix, S. _et al._ Is hepatic lipogenesis fundamental for NAFLD/NASH? A focus on the nuclear receptor coactivator PGC-1β. _Cell. Mol. Life Sci._ 73, 3809–3822 (2016). Article  CAS 

PubMed  Google Scholar  * Miyazaki, M. _et al._ Hepatic stearoyl-CoA Desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. _Cell Metab._ 6, 484–496

(2007). Article  CAS  PubMed  Google Scholar  * Postic, C. & Girard, J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: Lessons from

genetically engineered mice. _J. Clin. Invest._ 118, 829–838 (2008). Article  CAS  PubMed  PubMed Central  Google Scholar  * Lehenkari, P. P. _et al._ Further insight into mechanism of

action of clodronate: Inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. _Mol. Pharmacol._ 61, 1255–1262 (2002). Article  CAS  PubMed 

Google Scholar  * Malwal, S. R. _et al._ Bisphosphonate-generated ATP-analogs inhibit cell signaling pathways. _J. Am. Chem. Soc._ 140, 7568–7578 (2018). Article  CAS  PubMed  PubMed Central

  Google Scholar  * Conlon, D. M. _et al._ Inhibition of apolipoprotein B synthesis stimulates endoplasmic reticulum autophagy that prevents steatosis. _J. Clin. Invest._ 126, 3852–3867

(2016). Article  PubMed  PubMed Central  Google Scholar  * Kleiner, D. E. _et al._ Design and validation of a histological scoring system for nonalcoholic fatty liver disease. _Hepatology_

41, 1313–1321 (2005). Article  PubMed  Google Scholar  * Folch, J., Lees, M. & Sloane Stanley, G. A simple method for the isolation and purification of total lipides from animal tissues.

_J. Biol. Chem._ 226, 497–509 (1957). Article  CAS  PubMed  Google Scholar  * Severgnini, M. _et al._ A rapid two-step method for isolation of functional primary mouse hepatocytes: Cell

characterization and asialoglycoprotein receptor based assay development. _Cytotechnology_ 64, 187–195 (2012). Article  CAS  PubMed  Google Scholar  Download references ACKNOWLEDGEMENTS The

authors thank the Research Support Center, Graduate School of Medical Science, Kyushu University for technical support. This work was supported in part by the Japanese Society for the

Promotion of Science (JSPS) KAKENHI (Grant No. 26461383 to M.N.; Grant No. 25253008 to Y.M.). We thank Natasha Beeton-Kempen, Ph.D., from Edanz Group

(https://en-author-services.edanzgroup.com/) for editing a draft of this manuscript. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Division of Endocrinology and Metabolism, Department of

Internal Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan Nao Hasuzawa, Masaharu Kabashima, Rie Tokubuchi, Ayako Nagayama, Kenji Ashida, Yoshinori

Moriyama & Masatoshi Nomura * Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan Nao Hasuzawa, Keita

Tatsushima & Yoshihiro Ogawa * Department of Psychosomatic Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan Keita Tatsushima * Department of

Chemistry, Kurume University School of Medicine, Kurume, 830-0011, Japan Lixiang Wang Authors * Nao Hasuzawa View author publications You can also search for this author inPubMed Google

Scholar * Keita Tatsushima View author publications You can also search for this author inPubMed Google Scholar * Lixiang Wang View author publications You can also search for this author

inPubMed Google Scholar * Masaharu Kabashima View author publications You can also search for this author inPubMed Google Scholar * Rie Tokubuchi View author publications You can also search

for this author inPubMed Google Scholar * Ayako Nagayama View author publications You can also search for this author inPubMed Google Scholar * Kenji Ashida View author publications You can

also search for this author inPubMed Google Scholar * Yoshihiro Ogawa View author publications You can also search for this author inPubMed Google Scholar * Yoshinori Moriyama View author

publications You can also search for this author inPubMed Google Scholar * Masatoshi Nomura View author publications You can also search for this author inPubMed Google Scholar CONTRIBUTIONS

N.H., Y.O., Y.M., and M.N. designed the experiments and wrote the paper. N.H., K.T., L.W., M.K., and R.T. performed the experiments. N.H., K.T., L.W., A.N., K.A., Y.M., and M.N. analyzed

the data. N.H. is the guarantor of this work and, as such, has full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data

analysis. All authors read and approved the manuscript. CORRESPONDING AUTHOR Correspondence to Nao Hasuzawa. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no competing

interests. ADDITIONAL INFORMATION PUBLISHER'S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. SUPPLEMENTARY

INFORMATION SUPPLEMENTARY INFORMATION RIGHTS AND PERMISSIONS OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing,

adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons

licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise

in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the

permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Reprints and

permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Hasuzawa, N., Tatsushima, K., Wang, L. _et al._ Clodronate, an inhibitor of the vesicular nucleotide transporter, ameliorates steatohepatitis

and acute liver injury. _Sci Rep_ 11, 5192 (2021). https://doi.org/10.1038/s41598-021-83144-w Download citation * Received: 16 July 2020 * Accepted: 27 January 2021 * Published: 04 March

2021 * DOI: https://doi.org/10.1038/s41598-021-83144-w SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable

link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative